CD 1 — AR226-0000-0354

EPA administrative record segment: CD-1--AR226-0000-0354 (335 documents).

Page 1 of 4 — 335 documents
Title / Summary Year AR226 Docket Hash ID Pages
The document outlines ongoing research protocols by 3M and Johns Hopkins University to identify and analyze levels of various fluorochemicals, including PFOS and PFOA, in the sera of children in the United States, with final reports due in 2001 and 2004. 2001 AR226-0019 7R1892VG9X55Gr3JrRJvM1m46 4
This document outlines a study by 3M to determine the concentration ratios of perfluorooctanesulfonate (PFOS) in human liver, bile, and serum, with the aim of understanding tissue concentrations and their significance, following ethical guidelines for tissue procurement. 2001 AR226-0021 yGXqnpjkaQ6ZwVmM392mDGB3 3
The document reports on a study conducted by 3M Company to evaluate the acute oral toxicity of a material identified as T-2001CoC in male and female albino rats, finding an LD50 between 0.5 ml/kg and 2.5 ml/kg, with significant effects observed at higher dosage levels. 2001 AR226-0217 emRqj5b4MkoavYoOYbX7geON4 2
The document reports on a primary eye irritation study conducted by 3M Company on a test material (T-2001CoC) involving albino rabbits, concluding that the material is not a primary ocular irritant but requires cautionary labeling. 2001 AR226-0218 XzdmoX43R5zR7zOgoqNo3QOVR 3
The document details a primary skin irritation study conducted by 3M Company on a material (likely related to PFOA or PFOS) to assess its irritative effects on the skin of albino rabbits, following specific testing methods. 2001 AR226-0219 zQgQ4M1Dm4J0EON4VLGj8rMr7 3
The document announces that following negotiations, 3M will voluntarily phase out perfluorooctanyl sulfonate (PFOS) chemistry used in various products, with the EPA indicating it will monitor the phase-out and assess potential regulatory actions if necessary. 2000 AR226-0000 ykz222jZ3dvYZDMwzRDD9wYMr 1
This document is a correspondence from Larry R. Zobel of 3M to Dr. Oscar Hernandez at the US EPA, providing previously omitted documents related to studies on PFOS and PFOA, including a fertility and developmental toxicity study in rats. 2000 AR226-0001 mpOaeGv28OXkV5BY9NGa2RO5b 1
This correspondence from 3M's Medical Director, Larry R. Zobel, clarifies findings from a two-generation reproduction study on potassium perfluorooctanesulfonate (PFOS), stating that there were no significant effects on pup survival or growth at the 0.4 mg/kg/day dose, contrary to earlier reports. 2000 AR226-0002 oe5g96njYYw5307mKrVBp3ZnX 6
3M is voluntarily providing the EPA with additional information on perfluorooctanesulfonate (PFOS), including studies on pharmacokinetics, teratology, and epidemiology, as part of ongoing discussions regarding fluorochemistry. 2000 AR226-0003 nmZ079Gg25xEaoo7R305xEEO1 10
This document details a series of studies conducted by 3M on the dermal absorption and pharmacokinetics of perfluorooctanesulfonate (PFOS) in New Zealand white rabbits to assess the absorption capacity of low-molecular-weight manufacturing residuals. 2000 AR226-0009 gbnqByLxk1bJ3E4n8gZMZ56BL 4
The document summarizes an oral developmental toxicity study of potassium perfluorooctanesulfonate (PFOS) in rats, conducted by Riker Laboratories, which found maternal toxicity at the highest dose but no significant fetal toxicity, although a developmental eye abnormality was noted across all dose groups, leading to the conclusion that PFOS was teratogenic. 2000 AR226-0013 v19m6DyZ1YLy06agOOQLo0N4q 3
This final report from 3M Environmental Laboratory concludes that there was no detectable dermal absorption of FC-95 (the potassium salt of perfluorooctanesulfonic acid, or PFOS) in rabbits at low dose levels, indicating that these doses may be insufficient to assess dermal absorption. 2000 AR226-0011 QXqEZqrr9N5QL9DLEdn7b73b6 95
The document is a final report from 3M Environmental Laboratory detailing an analytical study on the pharmacokinetics of the fluorinated compound FC-95 (T-6049) in rabbits, which confirmed the presence of perfluorooctanesulfonate in liver and serum after intravenous dosing. 2000 AR226-0012 jB9rw4oRY4J64D9pO9KK8Qddk 82
The document outlines various analytical methods developed by 3M Environmental Laboratory for the extraction and analysis of Potassium Perfluorooctanesulfonate (PFOS) and other fluorochemicals from serum, liver, and urine using HPLC-Electrospray/Mass Spectrometry, detailing method numbers and adoption dates. 2000 AR226-0024 a4BNvgkVn1VwpZ9EQoVG222BR 15
This document is a correspondence from 3M confirming the submission of a non-confidential version of a toxicological study on perfluorooctane sulfonates to the EPA, following a request from EPA's Terry O'Brien. 2000 AR226-0037 Rjda4dkJ0EnNOXd4x2amgYXvz 1
This is a letter from the EPA's Office of Prevention, Pesticides and Toxic Substances, dated May 25, 2000, regarding information on perfluorooctane sulfonates, including a reference to additional studies and data submitted by 3M. 2000 AR226-0040 Lp1pYjZyn4enJgjnx41ggoX9z 5
3M is requesting a one-week extension to respond to the EPA's information request regarding perfluorooctane sulfonic acid (PFOS) due to operational disruptions and seeks to discuss interpretation questions related to previous communications with the EPA. 2000 AR226-0041 KRJvJEY2mV738X4294npky0M0 1
The document outlines various reports and studies conducted by 3M regarding the health effects of Perfluorooctanesulfonate (PFOS) on male employees at their fluorochemical production facilities, including epidemiological investigations and assessments of serum fluorochemical levels. 2000 AR226-0030 jwend2rXG0aYvx7yVkDee775 190
3M submitted a "Use and Exposure Information Profile" to the EPA detailing the use and exposure related to perfluorooctane sulfonic acid (PFOS) and its salt forms, emphasizing that the majority of their fluorochemical production involves higher molecular weight derivatives and that less than 200,000 lbs/year of PFOS and its salts are commercialized as finished products. 2000 AR226-0042 10vK5QrL2dLnN3z9OV2v9G0Ya 2
The document provides a voluntary use and exposure information profile for perfluorooctane sulfonate (PFOS) and its various salt forms produced by 3M Company, detailing their manufacturing process, site locations, and estimated distribution quantities. 2000 AR226-0043 penGV3Rw4jbrOL3zJwwRvDrQj 30
3M is providing the EPA with additional voluntary information on perfluorooctane sulfonates, including studies on their environmental properties and health effects, as part of ongoing discussions regarding fluorochemistry. 2000 AR226-0044 LJDJQxZJYrJx2wQxeE5OXyoZz 31
The document contains various laboratory reports and summaries related to the physical and chemical properties of perfluorooctanesulfonate (PFOS), including studies on its melting point, vapor pressure, partition coefficient, and solubility, conducted by Wildlife International, Ltd. and 3M Environmental Lab. 2000 AR226-0055 LJNLOOMVd8dRpXzxzkraR0NvX 39
The document outlines the design and structure of a Multi-City study submitted to 3M Environmental Laboratory, aimed at obtaining preliminary data on the dispersion of fluorochemical compounds, including PFOA, in the environment and their potential sources of human exposure. 2000 AR226-0063 DGQOz6M8jGX9EonnOQ7NBqd6o 7
The document contains attachments to a letter discussing various studies and information related to the acute toxicity and genotoxicity of perfluorooctane sulfonate (PFOS) and its derivatives, conducted by Biosearch, Inc. and Hazelton Washington for 3M. 2000 AR226-0291 3N8rQ6jL91aJR9axGKG058EqE 4
The document contains various studies and tests conducted by Riker Laboratories and other institutions on the acute toxicity, immunotoxicity, genotoxicity, and repeated-dose toxicity of N-ethylperfluorooctane sulfonamidoethyl acrylate (T-3493), a perfluorinated compound produced by 3M. 2000 AR226-0304 RJ8QJv6wBq94ZyLqN31Y200mX 10
The document details various toxicity studies conducted by Riker Laboratories, Inc. on the perfluorinated compound N-ethyl perfluorooctane sulfonamido ethyl methacrylate (T-3494), including acute oral toxicity, skin irritation, ocular irritation, immunotoxicity, and genotoxicity assessments. 2000 AR226-0312 99nqqz0q4va3QK1LJR1MQNMJL 10
This document contains studies and evaluations of the mutagenic activity of N-methylperfluorooctane sulfonamidoethyl acrylate (T-5869), conducted by NOTOX for 3M, including results from the Ames Salmonella test and chromosome aberration tests, all compliant with GLP standards. 2000 AR226-0317 x5OMKxbBN1kga1MpeOG2aEKyb 24
The document contains attachments related to studies on the acute toxicity and pharmacokinetics of perfluorooctane sulfonate (PFOS) and its derivatives, specifically detailing various toxicity tests conducted by 3M and other laboratories. 2000 AR226-0320 rB0vdVgqn01GvMd0GypLRD7e0 32
The document details a dietary acute study on the effects of perfluorooctanesulfonate (PFOS) conducted on mallard ducks, using a sample from 3M with a purity of 90.49%, to assess toxicity and establish LC50 values under controlled conditions. 2000 AR226-0102 LJB22x8Zw5bdR0Xwzz5Mkj2eQ 8
This document contains various studies and reports related to the genotoxicity and mutagenicity of perfluorooctane sulfonate (PFOS), including evaluations conducted by different laboratories and institutions, primarily focusing on Ames tests and chromosomal aberration assays. 2000 AR226-0128 J3LKnQbyByJRJGer4rVVgMzQX 12
The document evaluates mutagenicity studies on perfluorooctanesulfonate (PFOS), a degradation product of perfluorooctanesulfonylfluoride produced by 3M, to assess its potential mutagenic/genotoxic risks based on various toxicological studies conducted. 2000 AR226-0135 emXLYakkxVK3md08mq6JZr1ay 12
The document contains attachments related to various toxicity studies of Perfluorooctane Sulfonate (PFOS) conducted by the International Research and Development Corporation and Covance Laboratories, detailing findings from subacute and chronic studies in monkeys and rats. 2000 AR226-0137 baEVvZ7rxgONJBNYLao4vEy43 41
The document details the findings from a microscopic review of liver sections from rats in a chronic PFOS study, indicating that centrolobular hepatocyte hypertrophy is present in certain male groups, with some changes deemed adaptive and others potentially adverse, leading to a determination of NOAEL and NOEL for liver histologic changes. 2000 AR226-0141 K6e5Vp4Mdo5KYYekaxRwYayxo 11
3M submitted additional information to the EPA regarding perfluorooctane sulfonates and related compounds, including various CAS numbers, as part of ongoing discussions about fluorochemistry, while noting that some information is confidential business information. 2000 AR226-0333 BvMOL4jXQ1v8BOzxmrG5O1Mrm 20
The document announces that 3M will voluntarily phase out perfluorooctanyl sulfonate (PFOS) chemistry used in various products following negotiations with the EPA, with the agency committing to further evaluate potential risks to individuals and the environment. 2000 AR226-0000 jyNJq9dDR6pvKqbN4Zy9xOdrR 1
This document is a correspondence from Larry R. Zobel of 3M to Dr. Oscar Hernandez at the US EPA, providing additional documents related to studies on PFOS and PFOA that were inadvertently omitted from a previous package. 2000 AR226-0001 a4j4DeMN79KxBExEeL0n8QYNR 1
The document includes an exploratory 28-day oral toxicity study on PFOS and other chemicals, submitted by 3M under a claim of confidentiality, detailing the effects of these substances in rats. 2000 AR226-0153 Raq84pYqY9vovD7v35930BpEV 1
The document contains various studies and reports related to the pharmacokinetics and skin absorption of perfluorooctane sulfonate (PFOS) conducted by 3M, including multiple animal studies and analytical data submitted to the EPA. 2000 AR226-0154 20rJGqmaQR7J7n6qkje8B0D6 6
This document is a final report on an analytical study conducted by 3M, which investigates the pharmacokinetics of the perfluorinated compound FC-99 (T-6053) in rabbits, finding that fluorine was detected in liver tissue after a single intravenous dose of 20 µg/kg but not at lower doses, indicating that the perfluorooctanesulfonate 2000 AR226-0157 rx8RRqQm7JVDjV78zevE00Z9E 88
This document from 3M provides serum measurements of perfluorooctanesulfonate (PFOS) from two pharmacokinetic studies in rats, detailing the analytical results and offering assistance to the EPA in understanding the toxicological data. 2000 AR226-0160 zQXzQLzraLDVmbOo1mGV5Gp67 22
The document is a final report from 3M Environmental Laboratory detailing a single-dose dermal absorption/toxicity study of the perfluorinated compound FC-99 (T-6053) in rabbits, which found no significant differences in total organic fluorine levels between treated and control groups after 28 days. 2000 AR226-0158 XzxgyX81q28oNEg66a21qeXyw 135
The document outlines research proposals and studies conducted by Kendall B. Wallace at the University of Minnesota Duluth, focusing on the biochemical and molecular mechanisms of perfluoroalkyl sulfonamides, particularly perfluorooctane sulfonate (PFOS), with the aim of establishing methods to monitor health risks associated with exposure to perfluoroalkyl acids and their derivatives. 2000 AR226-0165 gLDeLYXJzEM8JmbDLV2DmaxQ 12
This report details the effects of a single acute dose of PFOS on catalase and acylCoA oxidase gene expression and enzyme activity in liver tissue from rats and guinea pigs, indicating the methodology and analysis used to assess these impacts. 2000 AR226-0171 XLg3bB1ORp2EgNB6pQr03oLG 6
The document discusses various studies and analyses related to perfluoroctane sulfonate (PFOS) in human sera, including blood testing results from Decatur workers and children, highlighting the relationship between organic fluorine concentrations in blood and exposure levels. 2000 AR226-0174 rxaKdJRQM1611BdzqVw98QvO7 7
The document is a final report of a pilot teratology study in rats (Project No. 154-158) conducted by Hazleton Laboratories for 3M, focusing on the effects of perfluoroctane sulfonate (PFOS). 2000 AR226-0173 QgQw2OVa6V40dNvmXdEnR1yQ5 48
The document outlines ongoing studies related to Perfluorooctane Sulfonic Acid Potassium Salt (PFOS) being conducted by Covance Laboratories and 3M, including a 104-week dietary chronic study in rats and a 26-week capsule toxicity study in cynomolgus monkeys, with interim data provided for both. 2000 AR226-0179 n9MBbQDvq1DOozBoZzQeEJZqX 12
This document outlines a research project by 3M, led by Deanna J. Luebker, aimed at investigating the mechanism by which perfluorooctane sulfonic acid (PFOS) induces adverse effects on peri-/postnatal development in rats, specifically through the inhibition of HMG-CoA reductase and potential mitigation of toxicity via mevalonate co-administration. 2000 AR226-0183 om5JbrNwQe5G1L7QXjYzdaYy3 16
The document outlines ongoing environmental studies on perfluorooctanesulfonates (PFOS) being conducted by various laboratories, including 3M Environmental Laboratory and Wildlife International, with expected completion dates for various toxicity tests and degradation studies in 2000. 2000 AR226-0184 z2zBg6wapDkpDdEZ84GZnpjz 12
The document outlines a planned one-generation reproduction study of perfluorooctane sulfonate (PFOS) in rats, focusing on pharmacokinetic analysis and involving various dose groups to assess the effects on pregnant rats and their pups. 2000 AR226-0192 5D95o5K9RVdVq0mGXeV1bZ4m4 5
This document outlines a draft study protocol for a one-generation reproduction study of PFOS in female Harlan CD rats, aiming to investigate whether co-administration of mevalonic acid or cholesterol can mitigate adverse maternal and fetal effects observed in a previous study, while also refining the no observed effect level (NOEL). 2000 AR226-0193 jXLRaDrO3Nk4aa2RMJ5NmwRk 5
The document provides data from 1974 environmental studies conducted by 3M on the acute toxicity of perfluorooctanesulfonate (PFOS) ammonium salt (FC-93) to fathead minnows, including details on the test substance composition and experimental conditions. 2000 AR226-0194 9JwgoZq3GYzwpbRz0bvqG7Z83 11
The document lists various acute toxicity studies conducted by Biosearch Inc. and Riker Laboratories on perfluorooctane sulfonate (PFOS) and related compounds, detailing the test subjects, methods, and dates of the studies. 2000 AR226-0197 rxKqzo06GgbMBXLQEJL2JDD2E 2
This document is an attachment to a letter discussing published studies on perfluorooctanesulfonates (PFOS) and perfluorooctanoic acid (PFOA), highlighting various environmental and toxicological research findings related to these perfluorinated compounds. 2000 AR226-0198 ZB9D6EY1vv9KOb4QbKk4kLYR0 2
3M is providing the EPA with additional information on perfluorooctylsulfonate (PFOS) salts, including their chemical designations and applications, as part of ongoing discussions regarding fluorochemistry. 2000 AR226-0200 per6mrMgkDzMRGK4JxVogOkZ6 3
This is a letter from Latham & Watkins to Dr. Charles Auer at the EPA, enclosing an analytical report from 3M's environmental monitoring program regarding perfluorinated materials, specifically detailing biosphere sampling and analysis results dated May 10, 2000. 2000 AR226-0201 QkVxR759XNK3GvxxprZxRvKaR 2
3M is providing supplemental information to the EPA regarding perfluorooctane sulfonates (PFOS), including executive summaries and a summary of a 26-week toxicity study in cynomolgus monkeys, to complete their previous submission. 2000 AR226-0203 93kqxkYX1G5ZZqL0rx2NZGa4L 8
3M is providing the EPA with additional information on perfluorooctane sulfonates and related compounds, including various CAS numbers, as part of ongoing discussions regarding fluorochemistry, while noting that some information is confidential business information. 2000 AR226-0204 xzwGQ6qyve3yw3zqjNZ51R5yE 51
The document contains a summary of acute toxicity studies related to perfluorooctane sulfonylamido (ethyl)acetate (PFOSAA) conducted by Biosearch, Inc. and Riker Laboratories for 3M, detailing various toxicity tests on rats and rabbits from 1978 to 1982. 2000 AR226-0216 aK3bX7308X2J7Qrowzzd1dna 5
The document contains various studies and reports from Hazelton Laboratories America, Inc. regarding the acute toxicity, genotoxicity, and pharmacokinetics of perfluorodecanesulfonate (PFDS) and other perfluorooctane sulfonate-related compounds, primarily conducted for 3M. 2000 AR226-0228 zdD75BOKoDzK77dpm6QzYQMQ7 17
This document is a final report of a pharmacokinetic study conducted by 3M on the test substance FC-129 (T-6054), which found that perfluorooctanesulfonate was a significant component of total organic fluorine detected in rabbit liver samples 48 hours after intravenous dosing. 2000 AR226-0226 0gNjxmw0xm92awVxbLgxNKGLn 96
This final report from 3M Environmental Laboratory details a dermal absorption and toxicity study of the perfluorinated compounds FC-129 (T-6051 and T-6054) in rabbits, finding that approximately 0.2% of the highest administered dose of FC-129 (12.8 mg/kg) was absorbed into the liver after 28 days. 2000 AR226-0225 GEQp32jj5LXb5RemELd26wyq 151
The document contains attachments to a letter discussing various acute toxicity and genotoxicity studies related to N-ethyl perfluorooctanesulfonamide (N-EtFOSA) and other perfluorooctane sulfonate-related compounds conducted by Riker Laboratories and Coming Hazelton, primarily focusing on tests performed on albino rats. 2000 AR226-0236 VGJv4j0pByo37ob8YXKer9n7g 15
The document is a final report from 3M Environmental Laboratory detailing a pharmacokinetic study of the perfluorinated compound FC-120 (T-6052) in rabbits, which found detectable organic fluorine levels in liver samples only at higher doses. 2000 AR226-0235 ZJRBb79xa28z2opQK1LNKrEKd 143
The final report from 3M's Environmental Laboratory indicates that a single-dose dermal absorption study of the perfluorinated compound FC-120 (T-6052) in rabbits showed no significant organic fluorine absorption at the highest dose of 1000 mg/kg, rendering the pharmacokinetic assessment unsuccessful. 2000 AR226-0234 Vdrj8Vqbxby17jw06b54rxng 183
The document contains various toxicity and genotoxicity study reports on N-methyl perfluorooctanesulfonamide (N-MeFOSA) conducted by Hazleton Laboratories for 3M, detailing acute oral toxicity, dermal irritation, eye irritation, and mutagenicity assays. 2000 AR226-0242 8RXa0E4QG0wqaRRqJGmr5OEe 51
The document contains attachments related to studies and information on perfluorooctane sulfonate (PFOS) and its related compounds, including acute toxicity, genotoxicity, and repeated-dose toxicity studies conducted by Hazelton Laboratories and International Research and Development Corporation. 2000 AR226-0249 V3QzppbGeaeyb9zwe0RKeQbL8 20
The document reports on a developmental toxicity study of N-EtFOSE (N-Ethyl-Perfluoroocyanesulfonamido Ethanol) in pregnant rabbits, finding that while there were dose-related effects on body weight and food consumption at higher doses, the compound was not teratogenic as no malformations were observed in the fetuses. 1999 AR226-0274 4JxG3zZB5QvJX2mRyOX4qOgRe 1
The document outlines a protocol for a study on N-EtFOSE (N-Ethyl perfluorooctanesulfonamido ethanol) conducted by 3M's Corporate Toxicology Department, aimed at developing methods for collecting urine and bile specimens from treated rats to support an ongoing ADME study in Cynomolgus monkeys. 1999 AR226-0288 zzNvL23Q3Q8MOm259gR66XGpB 7
This report evaluates the statistical quality of 12 data sources on serum perfluorooctanesulfonate (PFOS) levels in non-occupational human populations, finding that only pooled serum from U.S. blood banks was defensible for analysis, with a geometric mean PFOS blood level of 28.2 ppb. 1999 AR226-0036 ybzGXzkOYXxQZYqVE8vedNmd 10
The document reports the vapor pressure of perfluorooctanesulfonate (PFOS), produced by 3M Company, as 3.31 x 10^-4 Pa at 20°C, determined using the Spinning Rotor Gauge method under GLP conditions. 1999 AR226-0047 81je0jDyjOMwojaN7jrbRgpa 2
The document reports on a study conducted by Wildlife International, Ltd. for 3M Company to determine the n-octanol/water partition coefficient of perfluorooctanesulfonate (PFOS), which was ultimately deemed infeasible due to the formation of an inseparable emulsion during testing. 1999 AR226-0050 ydmV3r2ydwNGn3KQz3jwKEpE 3
The document reports on a study conducted by Wildlife International Ltd. to determine the vapor pressure of PFOS using the spinning rotor gauge method, sponsored by 3M Corporation, and completed on May 5, 1999, while noting some deviations from Good Laboratory Practice Standards. 1999 AR226-0048 aDxeN3gbZGebbM778pd2aZbGy 26
The document details a method developed by 3M's Environmental Laboratory to determine the air/water partition coefficient of perfluorooctanesulfonate (PFOS), indicating that the test substance was a white powder with unspecified purity and the experiment was completed in 1999 without following GLP standards. 1999 AR226-0051 J3vx6589XqXK85V7dg7BBLkae 10
The document reports on a water solubility test for Perfluorooctanesulfonate (PFOS) conducted by 3M, finding an overall mean solubility concentration of 519 mg/L in NANOpure water. 1999 AR226-0054 71MX9kO44B1ZJxZyovQVL25ve 22
The document reports on a study conducted by Wildlife International Ltd. for 3M Corporation to determine the water solubility of PFOS using the shake flask method, completed on May 3, 1999, with an amended report issued on April 26, 2000, and notes compliance with Good Laboratory Practice standards. 1999 AR226-0052 3Xx0EEzN7EyoBO5VoMYG2jgD 35
The document presents a fugacity modeling study of perfluorooctanesulfonate (PFOS), conducted by Don Mackay, which concludes that PFOS tends to remain in water when released, with slow degradation and significant persistence in the environment. 1999 AR226-0060 85oNVbVqLbaE21z9Ywqj3GomK 4
The document discusses the derivation of a draft lifetime Drinking Water Health Advisory (DWHA) for PFOS, based on a reference dose calculated using standard EPA methodology and a conservative uncertainty factor. 1999 AR226-0071 pBkok6KDNpkLGnL2dQyoOXGQE 6
The document outlines a review of field sampling procedures conducted by Battelle during a city survey in Columbus, Georgia, as part of the Multi-City Human Exposure Assessment Study, focusing on the appropriateness of sampling techniques for fluorochemicals, including PFOA and PFOS. 1999 AR226-0072 v1gmMdx7428ZBRgy4pEzMbQrZ 22
This is a field report from Battelle regarding a multi-city study conducted in Cleveland, Tennessee, and Decatur, Alabama, under Project Number N100672-01, focusing on the collection of samples for trace-level analysis of specific FC residuals. 1999 AR226-0073 LgxkewJ7YKGBOoqy0Oj6D2ObQ 16
This is a final field report from Battelle (Project Number N100672-01) detailing the multi-city study conducted in Columbus, Georgia, and Port St. Lucie, Florida, focusing on the collection of samples for trace-level analysis of FOSE-based fluorochemical residuals. 1999 AR226-0074 2G7YDyB9qO4Xd8oJdDdX24L7 16
The document is a final field report detailing the multi-city study conducted by Battelle in Mobile, Alabama, and Pensacola, Florida, focusing on the sampling and analysis of perfluorinated compounds, including PFOA and PFOS, as part of Project Number N100672-01. 1999 AR226-0075 O3mmmnVMXma5RjQ06BxqwLOyv 17
The document outlines a study protocol by 3M to assess cell proliferation and peroxisome proliferation in rats administered N-Ethyl Perfluorooctanesulfonamido Ethanol (N-EtFOSE), Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), and N-Ethyl Perfluoroctanesulfonamide (PFOSA) 1999 AR226-0290 ba6dYJ9mabjp2rVqD2nMn1pe0 14
The document discusses concerns regarding the conclusion of a dietary toxicity study on N-Methyl Perfluorooctanesulfonamido Ethanol (N-MeFOSE) conducted by Covance Laboratories, specifically questioning the determination of the no observable adverse effect level (NOAEL) and the biological significance of weight gain reductions at various dosage levels in rats. 1999 AR226-0301 3N3zO7mLL6wMEREV8mKV5BaD0 1
This document is an amendment to the Quality Assurance Project Plan for the Multi-City Study Sampling Task, prepared by Battelle, which outlines changes to sampling protocols, including the addition of labeling for 'Trip Blank' samples. 1999 AR226-0077 EdrZJm6RBzGKQDyvg7MMQMk4 23
This document details an acute toxicity study of Perfluorooctanesulfonate (PFOS) conducted on the fish species Pimephales promelas, using a sample from 3M with a purity of 90.49%, following OECD and OPPTS guidelines, and completed in 2000. 1999 AR226-0082 37LG6w3rrkXjem70vdJgobpxn 4
The document details a toxicity study of Perfluorooctanesulfonate (PFOS) conducted by 3M, which assessed its effects on the aquatic plant species Selenastrum capricornutum over a 96-hour exposure period, with a measured purity of 90.49%. 1999 AR226-0084 O3w4bNRw37BeaG8jmMpyxVorM 6
This document details an acute toxicity study of perfluorooctanesulfonate (PFOS) on the aquatic invertebrate Daphnia magna, conducted under OECD guidelines, with a purity of 90.49% and results indicating the EC50 values calculated for PFOS exposure. 1999 AR226-0086 ByJJOvMdM356evMxvpjaxvXmJ 4
The document details a study on the acute effects of perfluorooctanesulfonate (PFOS) on the shell growth of the Eastern oyster (Crassostrea virginica), using a sample from 3M with a purity of 90.49%, and outlines the methodology and statistical analysis used to determine the impact on shell growth over a 96-hour exposure period. 1999 AR226-0088 3wJvzz4rDyBve6N48MVkbDvJ 4
This document reports on an acute toxicity study of perfluorooctanesulfonate (PFOS) conducted on the freshwater mussel species Unio complanatus, detailing the test conditions, methods, and analytical results from a sample sourced from 3M. 1999 AR226-0090 bBkmJGd1gkOoj7GnLgq9de9y3 4
The document details an OECD 209 activated sludge respiration inhibition test conducted on perfluorooctanesulfonate (PFOS) sourced from 3M, which was found to have a purity of 90.49% and involved assessing its impact on dissolved oxygen concentrations in activated sludge from a wastewater treatment facility. 1999 AR226-0092 3Qeg0y5aZLQ1KVkB2V873dgoy 3
This document is an amended final report from Wildlife International Ltd. on a 96-hour shell deposition test conducted with the Eastern Oyster (Crassostrea virginica) to assess the effects of PFOS, sponsored by 3M Corporation, and it states compliance with Good Laboratory Practice standards while noting some exceptions in the characterization of the test substance. 1999 AR226-0089 npOzjNgaXknbXoN929OJwLMp8 56
This document is an amended final report of a 96-hour static acute toxicity test conducted by Wildlife International Ltd. on PFOS using the freshwater mussel (Unio complamatus), sponsored by 3M Corporation, and it outlines compliance with Good Laboratory Practice standards while noting exceptions in substance characterization and stability determination. 1999 AR226-0091 JJmomLXgrrDn7nG6mO76deKwK 59
The document details a study on the acute toxicity of perfluorooctanesulfonate (PFOS) to the saltwater mysid species Mysidopsis bahia, conducted by Wildlife International, Ltd., which determined the substance's purity to be 90.49% and involved a 96-hour exposure period to assess lethal concentration (LC50) values. 1999 AR226-0094 wgvXyayq5kLvwB0jbg9zpjM94 4
This document reports on a chronic toxicity study of perfluorooctanesulfonate (PFOS) conducted on early life stages of fish (Pimephales promelas) using a flow-through method, with a purity of 90.49% and significant statistical analysis performed to assess the effects of PFOS exposure over a 47-day period. 1999 AR226-0096 wggxnKLxKKybgwLa3KDLjpv14 5
This document details a chronic toxicity study of perfluorooctanesulfonate (PFOS) on freshwater invertebrates (Daphnia magna), conducted by Wildlife International, Ltd., which assessed survival, reproduction, and growth over a 21-day exposure period. 1999 AR226-0098 owG9V6zMowbewbkYBvdgKmdg 6
The document details a chronic toxicity study of Perfluorooctanesulfonate (PFOS) conducted on the saltwater mysid species Mysidopsis bahia, using a sample from 3M with a purity of 90.49%, and outlines the methods and statistical analyses employed to evaluate the effects of PFOS over a 35-day exposure period. 1999 AR226-0100 MJOy7n80RRY6Bx7oEwXOmDwLV 7
The document is a final report on an early life-stage toxicity test of PFOS conducted with fathead minnows (Pimephales promelas) by Wildlife International Ltd. for 3M Corporation, completed on April 26, 2000, and compliant with Good Laboratory Practice standards. 1999 AR226-0097 3m65nOZdQZqw4292L1011pL3 88
The document is a final report on a semi-static life-cycle toxicity test of PFOS conducted with the cladoceran Daphnia magna, sponsored by 3M Corporation and compliant with Good Laboratory Practice standards. 1999 AR226-0099 MMkZb1zMjEdxbZN6epvgvB50j 93
This document details a dietary acute study on the effects of perfluorooctanesulfonate (PFOS) on Northern bobwhite quail, conducted by Wildlife International Ltd., which involved testing the substance's concentration and stability in feed over a specified exposure period. 1999 AR226-0104 ypjrp1Gd56NkwjBdp4YkNOBLr 9
The document is a final report on a flow-through life-cycle toxicity test of PFOS conducted with the saltwater mysid (Mysidopsis bahia) by Wildlife International, Ltd. for 3M Corporation, indicating compliance with Good Laboratory Practice standards despite some exceptions in substance characterization. 1999 AR226-0101 kD2MNn8V78mkK9rx9BQLZj8XJ 76